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Sedation and analgesia performed by the pediatrician and pediatric subspecialists are becoming increasingly common for
diagnostic and therapeutic purposes in children with developmental disabilities and neurologic disorders (autism, epilepsy,
stroke, obstructive hydrocephalus, traumatic brain injury, intracranial hemorrhage, and hypoxic-ischemic encephalopathy). The
overall objectives of this paper are (1) to provide an overview on recent studies that highlight the increased risk for respiratory
complicationsfollowingsedationandanalgesiainchildrenwithdevelopmentaldisabilitiesandneurologicdisorders,(2)toprovide
abetterunderstandingofsedativesandanalgesicmedicationswhicharecommonlyusedinchildrenwithdevelopmentaldisabilities
and neurologic disorders on the central nervous system.
1.Introduction
With advances in health care, many children with develop-
mental disabilities and neurologic disorders are living longer
lives, and increasingly require diagnostic and therapeutic
interventions. Pediatricians and pediatric subspecialists are
increasing being called upon to safely sedate and provide
analgesia for these children for diagnostic procedures (CT,
MRI, angiogram, endoscopy, and bronchoscopy) and for
therapeuticinterventions(interventionalradiology,intracra-
nial injury, and emergency stabilization). This paper will
focus on children with developmental disabilities and neu-
rologic injury, and will highlight the risks involved with
these patients, and the eﬀects of common sedatives and
analgesic agents on the central nervous system. The purpose
of this paper is to provide the pediatrician and pediatric
subspecialistabetterunderstandingontheneurologiceﬀects
of diﬀerent sedative and analgesic medications so that
rational and safe choices can be used in children with
developmental disabilities and neurologic disorders without
causing further “neurologic” compromise.
2.MaterialsandMethods
We performed an extensive review of the medical literature
regarding sedation analgesia in children with developmen-
tal disability and neurologic disorders utilizing Pubmed.
Search terms included “sedation”, and “analgesia”, “pedi-
atric”, “child”, “neonate”, “brain”, “developmental disabili-
ties”, “neurologic”, “autism”, “epilepsy”, “seizure”, “stroke”,
“hydrocephalus”, “traumatic brain injury”, “intracranial
hemorrhage”, “hypoxia-ischemia”, and “encephalopathy”
and the period of search was from 1960–2010. The authors
are pediatric neurocritical care specialists and have extensive
clinical experience caring for pediatric patients with devel-
opmental disabilities and neurologic disorders and research
experience in experimental animal models of pediatric
neurologic injury.
3. Results and Discussion
3.1. Overview—Increased Risk for Respiratory Complications
following Sedation in Children with Developmental Disabil-
ities and Neurologic Disorders. Sedation and analgesia for2 International Journal of Pediatrics
the pediatric patient with developmental disabilities and
neurologic disorder require a thorough understanding of
potential adverse events, and the knowledge and skill to
avoid potentially life-threatening complications from the
administration of sedative and analgesic medications. In
addition, the practitioner must focus particular attention
on the entire periprocedural period including presedation
evaluation, sedation/analgesia administration, and recovery.
The American Academy of Pediatrics, Section on Anesthesi-
ology has published Guidelines for the Pediatric Perioperative
Anesthesia Environment, which includes suggestions for age
categorization, need for intensive care following sedation for
recovery, and presence of coexisting disease [1].
Since these guidelines were published, sedation outside
of the operating room continues to increase, along with the
varied practitioner’s disciplines that are delivering sedation.
With this practice increasing, the debate about safety and the
practitioner core competency requirements to provide seda-
tion and/or analgesia to the complex pediatric patient with
developmental disabilities and neurologic disorders has also
increased and several policy statements have been published
by diﬀerent professional societies [2], with no clear evidence
of practice standards and incidence of adverse outcomes. To
aid in the investigation of the practice and potential adverse
outcomes associated with the delivery of sedation outside the
operatingroom,thePediatricSedationResearchConsortium
(PSRC),acollectionof37institutionsthatshareinformation
on sedation practices within their individual institutions, has
created a self-reporting prospective, observational database.
This database has provided vital information to deﬁne the
frequency and nature of adverse events during pediatric
sedation from a multispecialty perspective [3]. Large PSRC
studies have shown a relatively low risk to pediatric sedation
by practitioners other than anesthesiologists [4]. However,
despite zero deaths in the 49,836 sedation encounters, one in
65 of these sedation encounters was associated with stridor,
wheezing, airway obstruction, laryngospasm, or central
apnea, conditions that all have the potential to deteriorate
to respiratory failure and death. Airway obstruction and
pulmonary complications were the most frequently cited
adverse event. In subsequent analysis, factors that related
to higher rates of pulmonary complications were young
patients, use of adjunctive opiates, and patients with a
higher American Society of Anesthesiology (ASA) status
(≥III), a large proportion with neurologic conditions [5].
This continues to emphasize that pediatric patients with
neurologic disorder and developmental disabilities receiving
sedation continue to be at increased risk for adverse events
with the most prevalent concerns for airway obstruction
and altered respiratory mechanics. Unfortunately, extensive
studies have not been performed to identify speciﬁc patients
at risk and aid in the development of evidence-based
clinical protocols for patients with neurologic pathology and
developmental disabilities. Most reported experience refers
to scattered case reports of speciﬁc syndromes (Butler et al.
has an excellent review of sedation complications related to
many speciﬁc syndromes [6]).
So what are the actual added risks associated with seda-
tion of the pediatric patient with developmental disabilities
or neurologic disorders? Brain MRI has become an impor-
tant diagnostic and management tool for these children
and is being increasingly used in many pediatric centers
[7]. Kannikeswaran and colleagues recently published a
retrospective review of children, 1–18 years of age, sedated
for brain MRI with and without developmental disability
[8]. Developmental disability is deﬁned by these investi-
gators as delay in one of the following: ﬁne/gross motor,
cognitive, speech/language, social/personal, and activities of
daily living. Pentobarbital and fentanyl were the two most
common medications used with no diﬀerence in mean
dosages between children classiﬁed as “normal” or “develop-
mental disability”. However, the patients classiﬁed as having
developmental disability had a threefold increased incidence
of hypoxia (11.9% versus 4.9%; P<. 01). These ﬁndings
seem to recapitulate the ﬁndings described in the PSRC
studies: an increase in adverse events, most notably airway
compromise, for children with developmental disabilities
and those with neurologic disorders. In this study, the most
common diagnosis for the cause of developmental disability
was autism (36%). In addition, the authors included patients
with attention deﬁcit hyperactivity disorder (20%) as a
diagnosis for developmental disability.
In another study, a small observational chart review
performed by Elwood et al. suggests that the anteroposterior
oropharyngeal airway diameter was smaller in children with
developmental delay than in those without developmental
delay, in static MRI images [9]. The limitations in this
study were the varied diagnoses within groups of patients
diagnosed with developmental delay without speciﬁc rec-
ommendations for certain patient populations. However,
it does reinforce the idea that sedation practitioners need
to exhibit marked vigilance for airway patency in patients
with developmental disabilities. In addition to a baseline
risk for airway compromise in patients with developmental
disability, Cortellazzi and colleagues showed that the risk for
airway obstruction signiﬁcantly increased in neurologically
impaired children undergoing MRI who were administered
a combination of sedative medications [10]. Thus, as
practitioners escalate pharmacologic intervention a patient
with developmental disabilities or neurologic disorders is
at increased risk for airway obstruction and may need
higher level of care, including the potential need for a
pediatric emergency medicine specialist, anesthesiologist, or
intensivist.
The choice of sedation plan varies by institution, prac-
titioner credentials, and experience. Protocols are based
on agent pharmacokinetic and pharmacodynamic proﬁles,
with an attempt to maintain a proper plane of seda-
tion and analgesia without respiratory and hemodynamic
compromise. However, virtually no protocol exists on the
use of diﬀerent sedatives and analgesic medications with
the focus on preventing “neurologic” compromise. While
there is not enough evidence-based data to support speciﬁc
clinical guidelines for sedation and analgesia in children
with developmental disabilities and neurologic disorders, the
authors’ hope is that the sedating practitioner will have a
better understanding to safely administer these medications
without promoting “further” neuronal injury.International Journal of Pediatrics 3
3.2. The Central Nervous System Eﬀects of Diﬀerent Sedative
and Analgesic Medications Commonly Used in Children with
Developmental Disabilities and Neurologic Disorders. The
practitioner must have a well-developed understanding of
the eﬀects that diﬀerent sedative and analgesic agents will
have on cerebral vasculature, metabolism, autoregulation
(maintaining constant cerebral blood ﬂow despite changes in
perfusionpressure),intracranialpressure(ICP),andcerebral
perfusion pressure (the perfusion pressure that causes blood
ﬂow to the brain); see Table 1 that provides the route and
dosages of the diﬀerent sedative and analgesic medications
that are commonly administered.
3.2.1. Opioids. Opioids, such as morphine, fentanyl, and
remifentanil, have long been considered eﬀective adjuvant
medications for analgesia of patients with developmental
disabilities and neurologic disorders. Opioids are very useful
in the treatment of nociceptive pain, and are crucial in
developing a balanced sedation plan when analgesia is a con-
cern, for example, intubation and comorbid injuries. Higher
doses of opioids can also have some degree of sedation
and even hypnosis; however, sedation is a side eﬀect and
not the intended pharmacodynamic purpose. Furthermore,
opioids lack amnestic properties, and therefore are rarely
used as sole agents for sedation in children. Opioids are
commonly coadministered with benzodiazepines, because of
their ability to provide sedation, amnesia, and hypnosis. Side
eﬀects of all opioids are similar, and include: constipation,
urinary retention, sedation, nausea, vomiting, respiratory
depression, bradycardia, hypotension, and pruritis.
Opioidpharmacologycanhaveeﬀectsonthecentralner-
vous system. Cerebral metabolic oxygen rate, cerebral blood
ﬂow (CBF), and ICP all decrease with the administration
of opioids if a patient’s arterial carbon dioxide (PaCO2)
remains unchanged. An increase in PaCO2 relaxes smooth
muscle, dilates cerebral vessels, decreases cerebrovascular
resistance, and increases CBF [11]. However, opioids have
minimal eﬀects on cerebral hemodynamics in adequately
resuscitated patients with controlled ventilation [12]. The
use of short-acting and ultra-short acting IV narcotics
(fentanyl, sufentanil, and remifentanil) via bolus infusion
and/or continuous infusion reported conﬂicting data on ICP
eﬀects[13–15].Opioidshaveadirecteﬀectontherespiratory
centers in the medulla, and decrease minute ventilation by
decreasing respiratory rate and produce a dose-dependent
depression of ventilatory response to carbon dioxide levels;
therefore, opioids decrease the apneic threshold which may
lead to hypoxia and respiratory failure. This side eﬀect may
be exacerbated in children with developmental disabilities
and neurologic disorders, who commonly have hypotonia,
central apnea, and inadequate airway reﬂexes.
Morphine,likemostnarcoticstendtodecreaseheartrate,
depending on the level of sympathetic output, through cen-
tral vagal stimulation. In addition to a negative chronotropic
eﬀect, morphine can lower mean arterial blood pressure
via arterial and venous dilation. Venodilation lasts longer
than arterial dilation and at increasing dosages will decrease
cardiac output and lower myocardial oxygen demands.
Because of these properties morphine is commonly admin-
istered in adults with myocardial ischemia; however, in
patients with traumatic brain injury a substantial decrease
in cardiac output and cerebral perfusion pressure may lead
to cerebral ischemia. Morphine administration results in
elevated histamine levels released from non-IgE-mediated
stimulation of mast cells. Histamine can result in decreased
systemic vascular resistance and an increased incidence
of pruritis in children. In children with developmental
disabilities and neurologic disorders it may be diﬃcult to
diﬀerentiate between increasing levels of agitation due to
pain or pruritis, and other side eﬀe c t s .T h et e r m i n a lh a l f -
life of morphine is higher in neonates, especially preterm
neonates,anddecreaseswithage;however,thereissigniﬁcant
individual variability in children. On average the terminal
half-life (t1/2) is approximately 9 hours in preterm infants,
6.5 hours in full-term neonates, and 2 hours in infants and
children.
Fentanyl has several advantages over morphine as an
adjuvant medication for analgesia in children with devel-
opmental disabilities and neurologic disorders. Fentanyl
crosses the blood brain barrier quickly and has a rapid
onset and relatively short oﬀset. In lower doses, fentanyl has
minimal eﬀects on cardiac output or respiratory depression
unless used in combination with other medications such
as benzodiazepines. Fentanyl is highly lipophilic and can
be administered by intranasal, transmucosal, or transdermal
routes. One of the major side eﬀects of fentanyl is that rapid
IV bolus can cause chest wall rigidity. In our intensive care
unit, fentanyl is the most common opioid used to provide
analgesia in postoperative patients with developmental dis-
abilities and neurologic disorders and is administered over
3 to 5 minutes when administered by the IV route. We
also commonly administer fentanyl in combination with
midazolam to provide sedation and analgesia for intubation
and mechanical ventilation.
Remifentanil is a potent ultra-short acting synthetic
opioid that has become a common component of total
intravenous anesthetics (TIVAs) especially for procedures
requiring neuromonitoring of somatosensory evoked poten-
tials (SSEP) and motor evoked potentials (MEP) in children
for neurosurgery and spinal surgery. The half life is 4
minutes, and unlike other synthetic opioids which are
metabolized by hepatic elimination, remifentanil is metab-
olized by nonspeciﬁc tissue and plasma esterases, thereby
eliminating accumulation. Remifentanil is also commonly
used in combination with other sedatives such as propofol
or midazolam for short painful procedures [16]. Signif-
icant dose-dependent bradycardia can be associated with
remifentanil administration. Due to the lack of eﬀect on
neuromonitoring, lack of accumulation, and short half life,
remifentanil can be used with great success by allowing the
practitionertheabilitytoquicklyadjustthedepthofsedation
for patients with neurologic disorders [17].
3.2.2.Benzodiazepines. Benzodiazepinesareparticularlyuse-
ful for sedation in pediatric patients with developmental dis-
abilitiesandneurologicdisordersbecauseoftheirpleiotropic4 International Journal of Pediatrics
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eﬀects: sedation, anxiolysis, muscle relaxation, and antero-
grade amnesia. Benzodiazepines also have anticonvulsant
eﬀects by enhancing the eﬀect of the neurotransmitter
gamma-aminobutyric acid (GABA) and is ideal for sedating
children with epilepsy. Signiﬁcant eﬀects on organ systems
include: decrease in blood pressure, depressed ventilation
(transient apnea, especially in combination with opioids),
andadecreaseincerebralmetabolicrate.Itisveryinteresting
to note that basic science research continues to try to
elucidatetheeﬀectofanesthetics,includingbenzodiazepines,
on the developing brain and neurocognitive function [18].
No traumatic brain injury studies, solely involving pediatric
patients, exist on the administration of commonly used
benzodiazepines (midazolam, lorazepam, diazepam). One
case series studied the eﬀects of diazepam in 7 adults and 1
adolescent with severe traumatic brain injury and revealed
a reduction in cerebral blood ﬂow and cerebral metabolic
rate with no eﬀect on blood pressure [19]. In our ICU, if
the fentanyl fails to control intracranial hypertension, and
as long as the hemodynamics are adequate, we will then
commonly administer a bolus IV dose of midazolam and
start a continuous IV infusion in a critically ill patient who
is intubated and mechanically ventilated.
Midazolam is a short-acting (unlike lorazepam and
diazepam), water-soluble benzodiazepine commonly used
for sedation in children with developmental disabilities
and neurologic disorders. Midazolam does not cause local
irritation after injection (unlike diazepam) and can be
readily mixed with other medications for intravenous, intra-
muscular, oral, intranasal, or rectal administration. Rapid
redistribution from the brain to other tissues, and rapid
metabolism by the liver, accounts for a short duration of
action and an elimination half life of 1 to 2 hours [20].
3.2.3. Barbiturates. Barbiturates, such as thiopental and
pentobarbital, have long been considered eﬀective seda-
tives for patients with neurologic disorders. Barbiturates
decrease cerebral blood ﬂow (CBF) and cerebral metabolic
rate (CMRO2) in a dose-dependent fashion but preserves
autoregulation [21]. Reductions in CBF and CMRO2 result
in a reduction in ICP which canbe useful fortraumatic brain
injury patients as well as acute stroke or intracranial hem-
orrhage patients with intracranial hypertension. In animal
studies, barbiturates have been observed to reduce infarct
size following focal cerebral ischemia [22]. Barbiturates’
neuroprotective characteristics are also related to reductions
in ischemia-induced glutamate release and inhibition of
intracellular calcium release [23, 24]. Barbiturates have
anticonvulsant properties and are ideal for sedating children
with seizure disorders.
Pentobarbital is a commonly used barbiturate for seda-
tion in children undergoing diagnostic radiologic imaging. It
can be administered orally or intravenously. Recovery time
can be prolonged following administration which may be
a concern if subtle changes in neurologic exam need to
be detected such as in the acute pediatric stroke patient.
Some pediatric patients may also experience severe agitation
during recovery which can confound sequential neurologic
examinations [25]. High-dose pentobarbital is also used as
a third tiered therapy to control intracranial hypertension
following severe traumatic brain injury in children but
the practitioner must be aware of the association with
hemodynamic instability and the need for blood pressure
supportwithintravenousﬂuidsandinotropicinfusions[26].
Besidesmyocardialdepressionandhypotension,barbitu-
rates also have the side eﬀect of respiratory depression which
can lead to hypoxia. This side eﬀect may be exacerbated in
children with developmental disabilities. In a retrospective
study, 260 children with developmental disabilities and
226 children without developmental disabilities undergoing
brain MRI with sedation were reviewed. No diﬀerence in
dosages of pentobarbital were observed between the two
groups but there was a threefold increased incidence of
hypoxia in children with developmental disability (11.9%
versus 4.9%) [8]. In summary, pentobarbital is commonly
used for sedation in children undergoing diagnostic radio-
logic procedures such as MRI or CT scan, but in the child
with developmental disabilities or neurologic disorders the
practitioner must be aware of the important side eﬀects
of systemic hypotension and respiratory depression and
be prepared to respond to them quickly to avoid further
neurologic injury.
Thiopental is an ultrashort-acting barbiturate which in
its IV form is commonly used as an induction agent for
intubation. The fast onset for induction and short duration
of eﬀect make it an attractive agent for rapid sequence
intubation in pediatrics. It still poses some of the risks
associatedwithbarbituratesincludingmyocardialdepression
and hypotension. The use of rectal thiopental (15–25mg/kg)
for sedation of pediatric patients undergoing diagnostic CT
imaging of the head has been reported to be eﬀective [27].
Due to the short duration of action, thiopental is generally
notusedforsedationduringMRIimagingduetolongerscan
times.
3.2.4. Etomidate. Etomidate is a short-acting IV drug that
produces sedation, anxiolysis, and amnesia. Side eﬀects
includerespiratorydepression,hypotension,myoclonus,and
adrenalsuppression.Etomidatehasthebeneﬁtsofdecreasing
ICPbyreductionsinCBFandCMRO2 andhastheadvantage
ofproducinglesscardiovasculardepressionthanbarbiturates
or propofol, and preserving cerebral perfusion pressure [28,
29]. These neuroprotective qualities are counterbalanced
by its ability to increase cerebral vascular resistance by a
greater magnitude than its reduction of CMRO2 resulting
in an increased metabolic deﬁcit [30, 31]. The increased
metabolic deﬁcit has the potential to expand the ischemic
core and penumbra in brain-injured tissue. This increase
in cerebrovascular tone is thought to be attributed to
etomidate’s inhibition of nitric oxide synthase [32].
Previous reports on the eﬃcacy of etomidate for pedi-
atric sedation during diagnostic imaging have been mixed.
Kienstra et al. performed a prospective randomized trial
comparingetomidate versuspentobarbitalforheadandneck
CT imaging in children 6 months to 6 years [33]. Sedation
success rate was signiﬁcantly lower in the etomidate group6 International Journal of Pediatrics
(57%–76% versus 97%) but the duration of sedation was
not surprisingly shorter in the etomidate group. Prospective
data collected from the PSRC also compared sedation with
pentobarbital versus etomidate for diagnostic CT [34]. Only
1 of 446 children sedated with etomidate was deemed “not
ideal sedation” compared to 11 of the 396 children who
received pentobarbital and duration of sedation was shorter
with etomidate (34 versus 144 minutes). Etomidate may
have a role for sedation during diagnostic CT imaging but
etomidate’s short duration of sedation is disadvantageous for
the longer scan times required for MRI. Of further note,
etomidate’s role in the sedation of the pediatric stroke and
intracranial hemorrhage patient may be limited and caution
should be used to avoid further expansion of the penumbra
and ischemic core.
3.2.5. Ketamine. Ketamine is a phenylcyclidine derivative
typically formulated as a mixture of two enantiomers in a
hydrochloridesaltform.Itpossess lowpH ofaround4which
can produce pain at the injection site when administered
intramuscularlyorintravenously.Ketaminecanprovideboth
sedation and analgesia. Ketamine is a N-methyl-D-aspartate
(NMDA) antagonist which produces increases in CBF and
CMRO2 [35, 36]. Early studies in patients with obstructed
CSF pathways reported ketamine administration increased
ICP with reductions in cerebral perfusion pressure [37, 38].
More recent studies in adult patients with severe head injury
have demonstrated improvements in cerebral perfusion
pressure and minimal increases in ICP with ketamine [39–
41]. One recent report of 30 intubated pediatric head injury
patients observed that single doses of ketamine lowered ICP
without producing decreases in blood pressure or cerebral
perfusion pressure [42]. However, it is still unclear regarding
the eﬀect of ketamine on ICP in patients where ventilation
is not being tightly controlled. At the present time, there is
not enough data to recommend the use of ketamine in the
pediatric population at risk for intracranial hypertension,
but further studies to assess the role of ketamine in this
patient population are warranted. Ketamine is sometimes
used as a continuous infusion in intubated patients as
an anti-convulsant for children with refractory epilepsy.
While ketamine is also a bronchodilator and is helpful
in children with asthma, it increases oropharyngeal and
airway secretions which may be problematic in children
with neurologic disorders who have diﬃculty handling
respiratory secretions. As a result, pretreatment with an
antisialogogue such as glycopyrrolate or atropine before
the administration of ketamine may be beneﬁcial. In older
children and adolescents, hallucinations and delirium can
occur; these patients are often premedicated with a short-
acting benzodiazepine such as midazolam.
3.2.6. Propofol. Propofol is a short-acting sedative-hypnotic
IV agent that can be used to provide moderate or deep
sedation. Propofol can induce a deep state of sedation
rapidly, provide a short duration of eﬀect, and have a
pleasantrecoveryphase[43].Propofolisaverypopularagent
for sedating pediatric patients with neurologic conditions
for noninvasive diagnostic imaging, such as a CT scan
or MRI. Due to the fast onset and recovery following
administration, repeated neurologic examinations are easy
to assess such as a child with sickle cell disease who comes
in with altered mental status due to a stroke. Propofol also
has anticonvulsant properties and reduces ICP which can
be advantageous in sedating a patient with epilepsy or a
patient with concerns for obstructive hydrocephalus due
to a malfunctioning ventriculoperitoneal shunt to obtain
diagnostic neuroradiologic imaging [44–46]. While there
have been cases of propofol providing adequate sedation
and successfully treating intracranial hypertension [47, 48],
several pediatric traumatic brain injury case reports have
reported metabolic acidosis and death in patients on pro-
longed (24 hrs) continuous infusion of propofol [49–53]. In
the 2003 published guidelines for the care of severe pediatric
traumatic brain-injured patients, “continuous infusion of
propofol is not recommended” [54].
Adverse eﬀects of propofol include pain at the injection
site, apnea or respiratory depression, hypotension, and
bradycardia which can be detrimental in a patient at risk
for brain ischemia. Propofol does not provide any analgesia.
As already discussed, a rare but potentially fatal “propofol
infusion syndrome”, associated with lactic acidosis, hyper-
lipidemia and multiorgan system failure was ﬁrst described
in pediatric patients who received prolonged (24 hours)
continuous infusion and at higher dosages (>4.5mg/kg/hr)
[51, 55, 56].
3.2.7. Dexmedetomidine. Dexmedetomidine, a centrally act-
ing α2-adrenergic agonist, is a recently FDA approved agent
used for short term (<24 hours) continuous IV sedation of
adults who are tracheally intubated. Like propofol, it has a
rapid onset and a relatively rapid elimination half life and
is administered as a loading dose followed by continuous
IV infusion. One of the advantages is that it provides
sedation with a lower risk of respiratory depression than
many other sedative medications [57] .T h e r ei si n c r e a s e d
interest with this agent as a sedative during non-invasive
neuroradiologic imaging studies in children who are not
intubated. In one study, dexmedetomidine was compared
to propofol in children undergoing MRI studies. While
the onset of sedation and recovery time were signiﬁcantly
shorter in the children that received propofol, hypotension,
respiratory depression and desaturation were more common
compared to the children receiving dexmedetomidine [58].
Thereisincreasedinterestintheuseofdexmedetomidine
as a sedative and potential neuroprotective agent in both
adults and children, as animal studies revealed neuropro-
tection from hypoxia-ischemia and decreased apoptosis and
adult human studies in healthy volunteers demonstrated
paralleldecreaseinCMRO2 andCBF,whichmaytemporarily
be helpful in brieﬂy sedating patients who are at risk
for intracranial hypertension such as head trauma, brain
tumor, and obstructive hydrocephalus [59, 60]. In pediatric
traumaticbraininjurycasereports,nodetrimentaleﬀectson
their ICP was observed. However, systemic hypertension was
observed in one child who were receiving dexmedetomidineInternational Journal of Pediatrics 7
with other sedatives, while bradycardia was observed in 2
other children who was receiving dexmedetomidine, other
sedatives, and therapeutic hypothermia [59, 60]. Further
studies are warranted on the potential use and side eﬀects
of this agent in children at risk for intracranial hypertension.
The most common adverse side eﬀects of dexmedeto-
midine appear to be cardiovascular. Bradycardia with rare
reports of sinus pause or cardiac arrest has been reported.
Hypotension has been reported as well as hypertension, the
latter thought to be due to peripheral α2B agonism with
peripheral vasoconstriction. There are conﬂicting reports
on the eﬀects of ventilatory function, with some studies
suggesting mild respiratory depression, while others show
no eﬀect. While ICP does not appear to increase, cerebral
perfusion pressure and CBF have been shown to decrease.
The eﬀects on seizure threshold appear to be mixed [61].
Further studies are warranted on the use of this agent in
pediatrics.
4. Conclusions
While a variety of sedative and analgesic medications
have been used in pediatric patients with developmental
disabilities and neurologic disorders, it is clear that further
studies are needed to determine the optimal agent(s) that
will maximize good outcome and will minimize or prevent
respiratory, circulatory, and further neurologic compromise.
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